AviaraDx, Mass General Cancer Center to Co-Develop Dx for Targeted Cancer Drugs | GenomeWeb

NEW YORK, May 17 (GenomeWeb News) - AviaraDx, formerly known as Arcturus Bioscience, and Massachusetts General Hospital Cancer Center plan to identify molecular profiles for multiple types of cancer, and hope to develop diagnostics that could help predict the way a patient may respond to certain targeted cancer drugs.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.